Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07104162 · ClinicalTrials.gov registry record · Phase 1
A Study to Investigate Safety and Pharmacokinetics of Intravenous Cefiderocol/Xeruborbactam in Participants With Renal Impairment
A Phase 1 study of Bacterial Infections, sponsored by Qpex Biopharma.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
- 2
- Study locations
NCT07104162: Recruiting Phase 1 study of Bacterial Infections, sponsored by Qpex Biopharma.
NCT07104162 is a Phase 1 study of Bacterial Infections that is actively recruiting participants, run by Qpex Biopharma. The registered enrollment target is 40 participants, below the 139-participant average among 17 other Bacterial Infections trials with a reported enrollment target (71% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07104162, a Phase 1 study of Bacterial Infections, is actively recruiting participants, sponsored by Qpex Biopharma.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
- 2
- Study locations
Study Summary
A Phase 1, Open-label, Single-dose Study to Determine the Safety and Pharmacokinetics of Intravenous Cefiderocol/Xeruborbactam (S-649228) in Participants with Renal Impairment
Primary Outcome
Number of participants with treatment-emergent adverse events by severity and relationship to treatment
Conditions Studied
Interventions
- DRUG Cefiderocol/Xeruborbactam
Study Locations (2)
Florida
- University of Miami Clinical Pharmacology - Miami
- Orlando Clinical Research Center - Orlando
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2025-09-16 |
| Est. Completion | 2026-12-23 |
| Phase | Phase 1 |
What NCT07104162 shows while recruiting
NCT07104162 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 139-participant average among 17 other Bacterial Infections trials with a reported enrollment target (71% lower).
The record links to 1 condition, with Bacterial Infections appearing as the primary indexed condition, and to 1 intervention - of which Cefiderocol/Xeruborbactam is the first listed.
NCT07104162 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT07104162 about?
NCT07104162 is a clinical study titled "A Study to Investigate Safety and Pharmacokinetics of Intravenous Cefiderocol/Xeruborbactam in Participants With Renal Impairment". A Phase 1, Open-label, Single-dose Study to Determine the Safety and Pharmacokinetics of Intravenous Cefiderocol/Xeruborbactam (S-649228) in Participants with Renal Impairment
What is the current status of trial NCT07104162?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2025-09-16. Estimated completion is 2026-12-23.
What conditions does trial NCT07104162 study?
This clinical trial studies the following conditions: Bacterial Infections.
What interventions are being tested in trial NCT07104162?
The interventions under investigation include: Cefiderocol/Xeruborbactam (DRUG).
Who is sponsoring clinical trial NCT07104162?
This trial is sponsored by Qpex Biopharma, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07104162 being conducted?
This trial has 2 study locations across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Bacterial Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07104162's enrollment target sits among peer trials
40 9th of 17 higher than 8 of 17 other Bacterial Infections trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Bacterial Infections trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
[18F]Fluoropropyl-Trimethoprim ([18F]F-TMP) PET/CT Imaging to Evaluate Biodistribution and Kinetics in Human Subjects
RECRUITING · Phase 1
-
Dose-finding, Pharmacokinetics, and Safety of VABOMERE in Pediatric Subjects With Bacterial Infections
ACTIVE NOT RECRUITING · Phase 1
-
Safety, Tolerability, Pharmacokinetics of Intravenous RPX2003 (Biapenem) in Healthy Adult Subjects
COMPLETED · Phase 1
-
Study of the Safety and Pharmacokinetics of KSP-1007 Alone and Coadministered With Meropenem in Healthy Subjects
COMPLETED · Phase 1
-
A Pilot of Pediatric/Adult Study of Gene Expression Profiling and Clinical Characterization of Phototoxicity
COMPLETED · Phase 1
-
PK & Safety Study of Xeruborbactam Oral Prodrug Combined With Ceftibuten in Participants With Renal Impairment
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI